Riken Immune Rejuvenation Medicine Co., Ltd. Offered by KWNA LLP (Tokyo - USA) in association with Guoyuan Securities Co. (Hong Kong)
A unique anti-cancer immunotherapy treatment to be offered in China and Hong Kong and IPO’d in 2019 Potential regional partners include Guoyuan Securities, China Merchant Bank and China Biotech Services
Riken’s Competitive Advantage • NK + T Therapy applied via 2 to 4 infusions • Dendric cells injected after culture is made of patient’s own blood • A NATURAL THERAPY WITH NO OUTSIDE DRUGS OR CHEMICALS • iNKT (invariant natural killer T) cells activated to fight cancer • SIMULTANEOUS NK + T ACTIVATION IS UNIQUE • Benefits remain active for 9 months in the body • UNIQUE LONG-LASTING BENEFITS • NK+T Therapy can be applied with other NK therapies • NKT OPERATES VIA A DIFFERENT MECHANIC
Regional Markets Identified • Japan • NKT therapy is licensed and is being applied to patients today. 81% success rate. • China PRC and Hong Kong • NK cell therapy is available but NKT will require regulatory approval (12 months) • Republic of Korea • NK cell therapy is available but NKT will require regulatory approval (9 months) • United States • NK cell therapy and altered T cell therapy in clinical trials stage. FDA approval some time away (36 months) • Europe • NK cell therapy and altered T cell therapy in clinical trials stage. Government approval some time away (36 months)
How does it work? Infusion introduces patient’s modified dendric cell TWO TREATMENTS 1 - NK activates your natural immune system 2 - Killer T cell activates your applied immune system RESULT success ratio of 81% upon treatment to level 4 cancer patients.
Business Plan Step 1 Step 2 Step 3 Step 4 • HK Holding • Other • Regional • NKT Company Regional Companies becomes a formed to Companies to offer Cancer hold all IP formed to therapy Prevention file required (JV’s with Therapy for • China JV IP and medical every formed and government company’s) person with operational approvals genetic pre- • Pre-IPO • IPO 2019 [SEED disposition funding ROUND] • IPO 2020+
Conclusion • IP Company will list in Hong Kong and IPO. Investors interested in the IPO and subsequent rounds should contact us at: • Kubo, Whang, Nolan and Amado LLP • Regional JV Partners and seed capital investors are needed in each specific region. • Regional partners should be capable of completing all IP applications and have strong government relationships for therapy approvals. • Where clinical trials are required for government licensing, JV Partners should have a proven track record of successful clinical trial management.
Recommend
More recommend
